系统性硬化症纤维化的国内外研究进展与现状分析
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i4.15504
Abstract
系统性硬化症(SSc)是一种病因未明的慢性结缔组织疾病,以皮肤及其附属结构异常纤维化为显著特点,目前尚无特效治疗方法,其主要治疗目标是缓解和改善患者的病况。本文旨在通过系统回顾和分析SSc的国内外研究进展与现状,揭示现有治疗方法的局限性,以及未来可能的研究方向和发展趋势,这为今后SSc治疗的研究提供了有益的参考和启示。
Keywords
系统性硬化症；纤维化；发病机制；治疗
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 刘梦玉.冯兴华教授应用补肾活血法治疗风湿病经验探析[D].北京中医药大学,2013.
[2] 李想,周于捷,张楠,等.基于TGF-β/Foxp3/RORγt通路探讨当归四逆汤治疗小鼠系统性硬化症的作用机制[J].中医学报[2024-10-24].
[3] 郭容宏,温鸿雁.白细胞介素家族在系统性硬化症中的作用[J].中华临床免疫和变态反应杂志,2023,17(05):450-454.
[4] 袁显墩,李照华,徐丹,等.丝氨酸蛋白酶23在系统性硬化病皮肤纤维化中的作用和机制[J/OL].北京大学学报(医学版),1-15[2025-09-09].
[5] 廖羽青,罗婧莹.Keap1-Nrf2-ARE信号通路与系统性硬化症氧化应激的研究进展[J].中国皮肤性病学杂志,2024,38(09):1053-1057.
[6] Li M, Liu Q,He S,et al.Icaritin Inhibits Skin Fibrosis through Regulating AMPK and Wnt/β-catenin Signaling[J].Cell biochemistry and biophysics,2021,79(2):231-238.
[7] 张羽,周雪艳,赵亮娟,等.博来霉素诱导系统性硬化病小鼠肠道菌群改变及醋酸泼尼松龙的干预作用[J].中国免疫学杂志,2023,39(11):2255-2264.
[8] Zhang M Y,Fang S,Gao H,et al.A critical role of AREG for bleomycin-induced skin fibrosis[J].Cell & Bioscience,2021,11: 1-10.
[9] Muraoka S, Brodie W D,Mattichak M N,et al.Targeting CD 13/aminopeptidase Nasa novel therapeutic approach for sclero derma fibrosis[J].Arthritis & Rheumatology.
[10] Bayati P,Poormoghim H,Mojtabavi N.Aberrant expressi on of miR-138 as a novel diagnostic biomarker in systemic sclerosis[J].Biomarker Insights,2022,17:11772719221135442.
[11] Steven O′Reilly.The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itacona te,Is Anti-Fibrotic in Systemic Sclerosis[J].Cells,2021,10.
[12] 谢美娟,吕小岩.抗纤维化药物在皮肤纤维化疾病中的应用进展[J/OL].中国皮肤性病学杂志,1-8[2024-10-15].
[13] Khanna D,Denton C P,Jahreis A,et al.Safety and effic acy of subcutaneous tocilizumab in adults with systemic scler osis (faSScinate):a phase 2,randomised,controlledtrial[J]. TheLa ncet,2016,387(10038).
[2] 李想,周于捷,张楠,等.基于TGF-β/Foxp3/RORγt通路探讨当归四逆汤治疗小鼠系统性硬化症的作用机制[J].中医学报[2024-10-24].
[3] 郭容宏,温鸿雁.白细胞介素家族在系统性硬化症中的作用[J].中华临床免疫和变态反应杂志,2023,17(05):450-454.
[4] 袁显墩,李照华,徐丹,等.丝氨酸蛋白酶23在系统性硬化病皮肤纤维化中的作用和机制[J/OL].北京大学学报(医学版),1-15[2025-09-09].
[5] 廖羽青,罗婧莹.Keap1-Nrf2-ARE信号通路与系统性硬化症氧化应激的研究进展[J].中国皮肤性病学杂志,2024,38(09):1053-1057.
[6] Li M, Liu Q,He S,et al.Icaritin Inhibits Skin Fibrosis through Regulating AMPK and Wnt/β-catenin Signaling[J].Cell biochemistry and biophysics,2021,79(2):231-238.
[7] 张羽,周雪艳,赵亮娟,等.博来霉素诱导系统性硬化病小鼠肠道菌群改变及醋酸泼尼松龙的干预作用[J].中国免疫学杂志,2023,39(11):2255-2264.
[8] Zhang M Y,Fang S,Gao H,et al.A critical role of AREG for bleomycin-induced skin fibrosis[J].Cell & Bioscience,2021,11: 1-10.
[9] Muraoka S, Brodie W D,Mattichak M N,et al.Targeting CD 13/aminopeptidase Nasa novel therapeutic approach for sclero derma fibrosis[J].Arthritis & Rheumatology.
[10] Bayati P,Poormoghim H,Mojtabavi N.Aberrant expressi on of miR-138 as a novel diagnostic biomarker in systemic sclerosis[J].Biomarker Insights,2022,17:11772719221135442.
[11] Steven O′Reilly.The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itacona te,Is Anti-Fibrotic in Systemic Sclerosis[J].Cells,2021,10.
[12] 谢美娟,吕小岩.抗纤维化药物在皮肤纤维化疾病中的应用进展[J/OL].中国皮肤性病学杂志,1-8[2024-10-15].
[13] Khanna D,Denton C P,Jahreis A,et al.Safety and effic acy of subcutaneous tocilizumab in adults with systemic scler osis (faSScinate):a phase 2,randomised,controlledtrial[J]. TheLa ncet,2016,387(10038).
Copyright © 2025 马思佳
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License